At the request of the US Food and Drug Administration, Pfizer Inc has suspended the clinical development programme for its investigational compound for osteoarthritis, tanezumab. The clinical hold follows reports of adverse events. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
